EXPEREO
10.4.2024 15:01:30 CEST | Business Wire | Press release
Expereo, the world leading global intelligent internet company that connects people, places and things anywhere today announces the appointment of Ben Elms as Chief Executive Officer and Irwin Fouwels as Executive Chairman, effective May 1st, 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410648166/en/
Ben Elms (Photo: Business Wire)
This strategic move is part of Expereo's commitment to driving sustained growth and building on its legacy of innovation and global customer success. With their combined experience in the telecommunications and technology sectors, Elms and Fouwels bring a wealth of expertise and leadership to their new roles within the business.
As CEO, Ben Elms will be responsible for driving the company's strategic vision, enhancing operational efficiency, and fostering innovation to meet the evolving needs of Expereo's global customer base. He brings over 25 years of relevant experience having held key executive roles at prominent firms and prior to joining Expereo as the CEO of Vodafone Global Enterprise Business, serving its multinational customers around the world.
Since joining in 2022 as Chief Revenue Officer, Elms has successfully led transformative initiatives such as expereoOne Expereo’s digital customer experience platform and driven its direct enterprise go-to-market strategy. This has positioned Expereo as a recognized global leader in delivering unique transformative customer value through its global enterprise network and cloud access solutions. In the first quarter of this year, Expereo launched its Enhanced Internet proposition, optimizing global cloud application performance through a proprietary AI-driven routing optimization platform. Leveraging Elms’ strong background in IoT and mobility, Expereo also added enterprise grade Fixed Wireless Access and Low Orbit Satellite solutions to its wide array of managed global connectivity solutions.
Elms commented; "I am honoured to lead Expereo during this exciting next phase of growth and innovation. Expereo has established itself as a global leader in internet-based connectivity solutions, and I look forward to working closely with the talented team to drive further success and deliver unparalleled value to our direct enterprise and wholesale customers. We have a strong foundation and a reputation for excellence in the industry. I am thrilled to lead the company with Irwin’s support as Executive Chairman. With the entire team we will capitalize on new opportunities, further expand our market presence, and drive continued innovation including driven by increased adoption of AI and the opportunities that creates for Expereo – “faster to the future”."
Fouwels, assuming the role of Executive Chairman brings a strategic mindset and a passion for innovation which has contributed to Expereo’s success. As Expereo CEO over the last decade, he has transformed and scaled Expereo to the world leading global intelligent internet company delivering unparalleled internet performance, led the company through multiple investor rounds and a series of acquisitions whilst delivering strong financial performance and investor returns.
Fouwels commented; “It is a privilege working with the global Expereo team and its investment partners over the last decade delivering unique value to our customers in a dynamic technology and telecoms market. We have been pivotal in transforming the way global enterprises architect global connectivity and application performance, leveraging the agility of the internet, whilst making it enterprise grade in terms of performance and security. And this anywhere on the globe, through any access technology.
Over the last two years Ben as CRO has been invaluable in accelerating our growth path, strengthening our go to market in direct enterprise whilst ensuring scalability throughout the organization, driving further automation, transformation and building global recognition of the Expereo brand and notably transforming expereoOne to a unique digital customer experience and platform. expereoOne turns the fragmented global internet landscape into a unique one-touch customer experience and has grown significantly with the addition of a large number of globally recognised large multinational enterprise customers. Ben has also brought in exceptional talent, strengthening the team as a foundation for further growth and solid financial performance. I am very much looking forward to working alongside Ben providing strategic guidance and supporting Expereo's leadership team”.
With Elms’ and Fouwels’ combined leadership, industry knowledge and track record of success they are confident in accelerating Expereo’s growth trajectory, and in delivering exceptional value to their customers and partners.
About Expereo
Expereo is the world leading intelligent internet company that connects people, places, and things anywhere. Solutions include Global Internet, SD-WAN/SASE, and Enhanced Internet. With an extensive global reach, Expereo is the trusted partner of 60% of Fortune 500 companies. It powers enterprise and government sites in more than 190 countries, with the ability to connect to any location worldwide, working with over 2,300 partners to help customers improve productivity and empowering their networks and cloud services with the agility, flexibility, and value of the Internet, with optimal network performance.
Expereo was acquired in Feb 2021, by Vitruvian Partners which acquired a majority shareholding from Seven2.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410648166/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom